These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8124846)

  • 1. Changing the course of diabetic nephropathy: angiotensin-converting enzyme inhibition in type I diabetic renal disease.
    Pohl MA
    Cleve Clin J Med; 1994; 61(1):38-42. PubMed ID: 8124846
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice.
    Katoh M; Ohmachi Y; Kurosawa Y; Yoneda H; Tanaka N; Narita H
    Eur J Pharmacol; 2000 Jun; 398(3):381-7. PubMed ID: 10862828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy.
    Björck S; Nyberg G; Mulec H; Granerus G; Herlitz H; Aurell M
    Br Med J (Clin Res Ed); 1986 Aug; 293(6545):471-4. PubMed ID: 3017501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
    Fournier A; Lalau JD
    N Engl J Med; 1994 Mar; 330(13):937; author reply 938. PubMed ID: 8114873
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
    Parving HH
    N Engl J Med; 1994 Mar; 330(13):937-8. PubMed ID: 8114875
    [No Abstract]   [Full Text] [Related]  

  • 6. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA; Firth LM; Lewis EJ
    Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
    Lopez A; Marantz PR
    N Engl J Med; 1994 Mar; 330(13):937; author reply 938. PubMed ID: 8114874
    [No Abstract]   [Full Text] [Related]  

  • 8. Angiotensin converting enzyme inhibition in diabetic nephropathy. The Collaborative Study Group.
    Breyer JA; Hunsicker LG; Bain RP; Lewis EJ
    Kidney Int Suppl; 1994 Feb; 45():S156-60. PubMed ID: 8158886
    [No Abstract]   [Full Text] [Related]  

  • 9. [Usefulness of angiotensin converting enzyme inhibitors in the treatment of diabetic nephropathy].
    Romero R; Sanmartí A; Salinas I; Teixidó J; Foz M; Caralps A
    Med Clin (Barc); 1988 Mar; 90(12):494-6. PubMed ID: 3292854
    [No Abstract]   [Full Text] [Related]  

  • 10. Longitudinal evaluation of renal function in non-insulin-dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition.
    Vora JP; Leese GP; Peters JR; Owens DR
    J Diabetes Complications; 1996; 10(2):88-93. PubMed ID: 8777336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
    Parving HH; Jacobsen P; Tarnow L; Rossing P; Lecerf L; Poirier O; Cambien F
    BMJ; 1996 Sep; 313(7057):591-4. PubMed ID: 8806248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.
    Parving HH; Hommel E; Jensen BR; Hansen HP
    Kidney Int; 2001 Jul; 60(1):228-34. PubMed ID: 11422755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
    Lewis EJ; Hunsicker LG; Bain RP; Rohde RD
    N Engl J Med; 1993 Nov; 329(20):1456-62. PubMed ID: 8413456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy.
    Parving HH; Hommel E; Damkjaer Nielsen M; Giese J
    BMJ; 1989 Aug; 299(6698):533-6. PubMed ID: 2507061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice.
    Yotsumoto T; Naitoh T; Shikada K; Tanaka S
    Jpn J Pharmacol; 1997 Sep; 75(1):59-64. PubMed ID: 9334886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmaclinics. Drug of the month. Captopril (Capoten) in diabetic nephropathies].
    Scheen AJ
    Rev Med Liege; 1995 Oct; 50(10):445-6. PubMed ID: 7491445
    [No Abstract]   [Full Text] [Related]  

  • 17. Captopril for diabetic nephropathy.
    Med Lett Drugs Ther; 1994 May; 36(923):46-7. PubMed ID: 8177138
    [No Abstract]   [Full Text] [Related]  

  • 18. Diabetic nephropathy.
    Shlipak M
    Clin Evid; 2004 Dec; (12):814-33. PubMed ID: 15865682
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy.
    Villa E; Rábano A; Cazes M; Cloarec A; Ruilope LM; García-Robles R
    Am J Hypertens; 1997 Mar; 10(3):275-81. PubMed ID: 9056684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting enzyme-inhibition in diabetic nephropathy.
    Mathiesen ER; Parving HH; Hommel E
    Contrib Nephrol; 1989; 73():160-1; discussion 161-2. PubMed ID: 2689092
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.